Sophie Corvaisier

Caen, 14000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Enhancing brain delivery of tegaserod for Alzheimer's disease: a pharmaceutical comparison of two nanocarrier-based strategies.

Enhancing brain delivery of tegaserod for Alzheimer's disease: a pharmaceutical comparison of two nanocarrier-based strategies.

Journal: International journal of pharmaceutics

Published: April 03, 2026

Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes.

Fenofibrate as an anti-cancer treatment: an in vitro study on glioblastoma cells at various oxygen levels and on normal astrocytes.

Journal: Cancer cell international

Published: October 01, 2025

LOU/c/jall rat as a model of resilience in the context of streptozotocin-induced cognitive impairment.

LOU/c/jall rat as a model of resilience in the context of streptozotocin-induced cognitive impairment.

Journal: Frontiers in aging neuroscience

Published: July 15, 2025

Early involvement of D-serine in β-amyloid-dependent pathophysiology.

Early involvement of D-serine in β-amyloid-dependent pathophysiology.

Journal: Cellular and molecular life sciences : CMLS

Published: February 03, 2025

Synthesis, in vitro and in vivo biological evaluation of novel dual compounds targeting both acetylcholinesterase and serotonergic 5-HT4 receptors with potential interest in the treatment of Alzheimer's disease.

Synthesis, in vitro and in vivo biological evaluation of novel dual compounds targeting both acetylcholinesterase and serotonergic 5-HT4 receptors with potential interest in the treatment of Alzheimer's disease.

Journal: European journal of medicinal chemistry

Published: September 20, 2024

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer's disease by administration through an intranasal route.

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer's disease by administration through an intranasal route.

Journal: Communications biology

Published: January 03, 2024

A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs.

A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs.

Journal: International journal of molecular sciences

Published: October 27, 2023

Novel thienopyrimidones targeting hepatic and erythrocytic stages of Plasmodium parasites with increased microsomal stability.

Novel thienopyrimidones targeting hepatic and erythrocytic stages of Plasmodium parasites with increased microsomal stability.

Journal: European journal of medicinal chemistry

Published: July 03, 2023

New antiplasmodial 4-amino-thieno[3,2-d]pyrimidines with improved intestinal permeability and microsomal stability.

New antiplasmodial 4-amino-thieno[3,2-d]pyrimidines with improved intestinal permeability and microsomal stability.

Journal: European journal of medicinal chemistry

Published: September 12, 2022

Improving Aqueous Solubility and In Vitro Pharmacokinetic Properties of the 3-Nitroimidazo[1,2-a]pyridine Antileishmanial Pharmacophore.

Improving Aqueous Solubility and In Vitro Pharmacokinetic Properties of the 3-Nitroimidazo[1,2-a]pyridine Antileishmanial Pharmacophore.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 22, 2022

In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.

In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.

Journal: International journal of pharmaceutics

Published: July 18, 2022

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 16, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026